Anti P2X
The invention relates to an antigen binding site for binding to a P2X 7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
1. An antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula:
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
wherein:
FR1, FR2, FR3 and FR4 are each framework regions;
CDR1, CDR2 and CDR3 are each complementarity determining regions;
wherein:
CDR1 has a sequence: PMKDMG SEQ ID NO: 49;
CDR2 has a sequence: AISGSGGGTYYADSVKG SEQ ID NO: 110;
CDR3 has a sequence: EPKPMDTEFDY SEQ ID NO: 9.
2. An antigen binding site for binding to a P2X7 receptor according to claim 1 , wherein
FR4 has a sequence: WGQGTLVTVSS SEQ ID NO: 153, WGQGTLVTVLS SEQ ID NO: 154, RSPGTLVTVSS SEQ ID NO: 155, PSPGTQVTVSS SEQ ID NO: 156, PSPGTLVTVSS SEQ ID NO: 157, RSQGTLVTVSS SEQ ID NO: 158, WSQGTLVTVSS SEQ ID NO: 159, RGQGTLVTVSS SEQ ID NO: 160, RFQGTLVTVSS SEQ ID NO: 161, WSPGTLVTVSS SEQ ID NO: 162, GSPGTLVTVSS SEQ ID NO: 163, WGPGTLVTVSS SEQ ID NO: 164, RGPGTLVTVSS SEQ ID NO: 165, CGPGTLVTVSS SEQ ID NO: 166, or RSCGTLVTVSS SEQ ID NO: 167.
3. A nucleic acid encoding an antigen binding site according to claim 1 .
4. A method for the treatment of cancer that expresses non-functional P2X 7 receptor in an individual including the step of administering an antigen binding site according to claim 1 to an individual requiring treatment for said cancer.
5. An antigen binding site for binding to a P2X7 receptor according to claim 2 , wherein
FR1 has a sequence: EVQLLESGGGLVQPGGSLRLSCAASGYTF SEQ ID NO: 142.
6. An antigen binding site for binding to a P2X7 receptor according to claim 5 , wherein
FR2 has a sequence: WVRQAPGKGLEWVS SEQ ID NO: 145.
7. An antigen binding site for binding to a P2X7 receptor according to claim 6 , wherein
FR3 has a sequence: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SEQ ID NO: 148.
8. A nucleic acid of claim 3 , wherein
FR4 has a sequence: WGQGTLVTVSS SEQ ID NO: 153, WGQGTLVTVLS SEQ ID NO: 154, RSPGTLVTVSS SEQ ID NO: 155, PSPGTQVTVSS SEQ ID NO: 156, PSPGTLVTVSS SEQ ID NO: 157, RSQGTLVTVSS SEQ ID NO: 158, WSQGTLVTVSS SEQ ID NO: 159, RGQGTLVTVSS SEQ ID NO: 160, RFQGTLVTVSS SEQ ID NO: 161, WSPGTLVTVSS SEQ ID NO: 162, GSPGTLVTVSS SEQ ID NO: 163, WGPGTLVTVSS SEQ ID NO: 164, RGPGTLVTVSS SEQ ID NO: 165, CGPGTLVTVSS SEQ ID NO: 166, or RSCGTLVTVSS SEQ ID NO: 167.
9. A nucleic acid of claim 8 , wherein
FR1 has a sequence: EVQLLESGGGLVQPGGSLRLSCAASGYTF SEQ ID NO: 142.
10. A nucleic acid of claim 9 , wherein
FR2 has a sequence: WVRQAPGKGLEWVS SEQ ID NO: 145.
11. A nucleic acid of claim 10 , wherein
FR3 has a sequence: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SEQ ID NO: 148.
12. A method of claim 4 , wherein
FR4 has a sequence: WGQGTLVTVSS SEQ ID NO: 153, WGQGTLVTVLS SEQ ID NO: 154, RSPGTLVTVSS SEQ ID NO: 155, PSPGTQVTVSS SEQ ID NO: 156, PSPGTLVTVSS SEQ ID NO: 157, RSQGTLVTVSS SEQ ID NO: 158, WSQGTLVTVSS SEQ ID NO: 159, RGQGTLVTVSS SEQ ID NO: 160, RFQGTLVTVSS SEQ ID NO: 161, WSPGTLVTVSS SEQ ID NO: 162, GSPGTLVTVSS SEQ ID NO: 163, WGPGTLVTVSS SEQ ID NO: 164, RGPGTLVTVSS SEQ ID NO: 165, CGPGTLVTVSS SEQ ID NO: 166, or RSCGTLVTVSS SEQ ID NO: 167.
13. The method of claim 12 , wherein
FR1 has a sequence: EVQLLESGGGLVQPGGSLRLSCAASGYTF SEQ ID NO: 142.
14. The method of claim 13 , wherein
FR2 has a sequence: WVRQAPGKGLEWVS SEQ ID NO: 145.
15. The method of claim 14 , wherein
FR3 has a sequence: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA SEQ ID NO: 148.